首页 | 本学科首页   官方微博 | 高级检索  
检索        

注射用兰索拉唑在健康人体内单、多剂量的药动学研究
引用本文:张伟,秦玉花,赵红卫,丁祖锐,赵钰敏,纪红英.注射用兰索拉唑在健康人体内单、多剂量的药动学研究[J].中国新药与临床杂志,2008,27(2):89-93.
作者姓名:张伟  秦玉花  赵红卫  丁祖锐  赵钰敏  纪红英
作者单位:1. 河南省人民医院药剂科,河南郑州,450003
2. 郑州大学化学系,河南郑州,450052
摘    要:目的研究注射用兰索拉唑在中国健康人体内的单、多剂量药动学。方法24名健康志愿者随机分为3组,每组8人(男女各半),分别恒速静脉注射15、30、60 mg兰索拉唑进行单剂量药动学研究,30 mg剂量组继续给药,qd×7d,进行多剂量药动学研究。按试验方案采血,用高效液相色谱法测定血药浓度,DAS 2.0程序计算药动学参数。结果健康受试者单剂量给药15、30、60 mg兰索拉唑后主要的药动学参数分别为t_(max)(0.669±s 0.014)、(0.667±0.012)、(0.668±0.013)h;c_(max)(1.01±0.05)、(1.69±0.06)、(3.01±0.08)mg·L~(-1);AUC_(0~t)(3.8±0.3)、(6.5±0.3)、(10.26±0.24)mg·h·L~(-1);t_(1/2)(1.8±0.6)、(3.4±0.8)、(2.5±0.5)h。多剂量给药30 mg达稳态时,主要的药动学参数为t_(max)(0.668±0.011)h;c_(max)(1.74±0.05)mg·L~(-1);c_(min)(0.125±0.012)mg·L~(-1);AUC_(?)(6.5±0.3)mg·h·L~(-1);t_(1/2)(3.0±0.9)h;CL (3.8±0.4)L.h~(-1);c_(av)(0.271±0.014)mg·L~(-1);DF(6.0±0.4)%。结论兰索拉唑在连续多次给药后,体内无蓄积现象,血药浓度d4已达稳态。兰索拉唑剂量的增加与C_(max)、AUC_(0~1)和AUC_(0~∞)的增加呈正相关关系;兰索拉唑的体内过程在男女性别间无显著差异。

关 键 词:兰索拉唑  药动学  色谱法,高压液相
文章编号:1007-7669(2008)02-0089-05
收稿时间:2007-10-15
修稿时间:2008-01-09

Study on pharmacokinetics of single and multi-dose lansoprazole injection in healthy volunteers
ZHANG Wei,QIN Yu-hua,ZHAO Hong-wei,DING Zu-rui,ZHAO Yu-min,JI Hong-ying.Study on pharmacokinetics of single and multi-dose lansoprazole injection in healthy volunteers[J].Chinese Journal of New Drugs and Clinical Remedies,2008,27(2):89-93.
Authors:ZHANG Wei  QIN Yu-hua  ZHAO Hong-wei  DING Zu-rui  ZHAO Yu-min  JI Hong-ying
Abstract:AIM To study the pharmacokinetics of lansoprazole injection with a single and multiple-dose intravenous injection administration using a constant speed in Chinese healthy volunteers.METHODS Twenty- four healthy volunteers were randomly divided into three groups,with 4 males and 4 females in each group.The volunteers in three groups were administrated with single dose of lansoprazole 15,30,60 mg,respectively, and those who got dose of 30 mg were administrated once a day till seventh day.Blood samples were collected according to the protocol and serum concentrations of lansoprazole,and in term were measured by validated high pressure liquid chromatography(HPLC).DAS2.0 pharmacokinetic program was performed for calculating pharmacokinetic parameters.RESULTS The main pharmacokinetic parameters of lansoprazole in volunteers who were administrated with a single dose of 15,30,60 mg were as follows:t_(max)(0.669±s0.014),(0.667±0.012),(0.68±0.013) h;c_(max)(1.01±0.05),(1.69±0.06),(3.01±0.08) mg·L~(-1);AUC_(0-t)(3.8±0.3), (6.5±0.3),(10.26±0.24) mg·h·L~(-1);t_(1/2)(1.8±0.6),(3.4±0.8),(2.5±0.5)h;respectively.The main pharmacokinetic parameters of lansoprazole after multiple-dose(30 mg)administration were as follows:t_(max) (0.68±0.011) h;c_(max)(1.74±0.05) mg·L~(-1);c_(min)(0.125±0.012) mg.L~(-1);AUC_(ss)(6.5±0.3) mg·h·L~(-1); t_(1/2) (3.0±0.9)h;CL(3.8±0.4) L·h~(-1);c_(av)(0.271±0.014) mg·L~(-1);DF(6.0±0.4)%.CONCLUSION After administration of multiple-dose lansoprazole,no accumulation occur in vivo.Serum concentrations of lansoprazole have been in steady state till fourth day.Increase of lansoprazole dosage is positively calculated with increase of c_(max),A UC_(0-t) and A UC_(0-∞) and simultaneously with no significant difference of physiological disposition between the male and female.
Keywords:lansoprazole  pharmacokinetics  chromatography  high pressure liquid
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号